Palantir’s Stormy Week: A UK Contract Challenge, Insider Exodus, and an AGM Clash Over Ethics

Palantir faces UK parliamentary threat to end NHS contract, record insider sales, and investor revolt over human rights at its AGM.

The confluence of political pressure, shareholder activism, and a fresh regulatory shock is testing Palantir’s narrative of unstoppable growth. Within days, the data analytics group has been hit by a UK parliamentary committee’s demand to terminate a major NHS contract, a record wave of insider stock sales, and a Trump-era executive order that sent shares sliding. All this unfolds just as the company holds its annual general meeting, where institutional investors are mounting an unusual public revolt over human rights concerns.

London’s Warning on National Security

A cross-party science committee in the House of Commons has branded Britain’s reliance on Palantir an “unacceptable vulnerability.” The panel, led by chair Chi Onwurah, is urging the government to invoke an exit clause in the NHS data platform agreement — a seven-year, £330?million contract that is part of a broader £670?million portfolio Palantir holds with UK authorities, including a £240?million defence ministry deal. The clause becomes exercisable in February 2027.

Palantir’s UK chief, Louis Mosley, dismissed the recommendation as “simply irresponsible,” arguing the technology accelerates cancer diagnoses and delivers measurable patient benefits. The political pressure in London comes as the group’s stock trades at €130.38 on the Frankfurt exchange, roughly 27% below its 52-week high and just under the 200-day moving average. The relative strength index (RSI) of 86 signals overbought conditions despite a 15% rally over the past seven days.

Insider Selling at Record Pace

While politicians debate the NHS relationship, Palantir’s own top brass have been cashing out. Over the past three months, insiders sold shares worth $45.3?million across 113 transactions, with zero purchases. The most recent filings show chief technology officer Shyam Sankar disposed of 165,514 shares for roughly $22.51?million, while director Lauren Friedman sold 3,265 shares worth about $505,000.

The selling spree adds a layer of unease as the company navigates its AGM, where governance and ethics are front and centre.

AGM Showdown Over Human Rights

Palantir’s AGM on Wednesday features two shareholder proposals that have drawn backing from some of the world’s largest institutional investors. Norges Bank Investment Management, which oversees Norway’s $2.3?trillion sovereign wealth fund, intends to vote for resolutions demanding a human rights impact assessment and greater transparency around political spending. The proposals are supported by investors with at least $336?billion in combined assets under management, arguing that Palantir’s software is used by state and non-state actors to infringe on rights such as freedom of movement, privacy, and due process.

Additional pressure comes from New York City’s comptroller, who in February urged an independent human rights review of Palantir’s work with the Department of Homeland Security. The Netherlands’ largest pension fund, ABP, has already divested, and Norway’s Storebrand — with roughly $109?billion under management — also exited, citing sales to Israel for use in occupied Palestinian territories.

Despite the institutional chorus, the proposals have almost no chance of passing. Palantir’s Class F shares give founders Peter Thiel, Alex Karp, and Stephen Cohen up to 49.999999% of total voting rights as long as they maintain minimum ownership thresholds. The board recommends voting against both motions, arguing Palantir is not a surveillance company, does not trade in personal data, and that legal and national security constraints limit disclosure.

Trump’s AI Order Adds a Regulatory Headwind

Just a day before the AGM, a fresh presidential directive from Donald Trump sent the stock down 5.3%. The executive order requires companies to participate in a government benchmarking programme for AI systems, granting the state access to models up to 30 days before public release and a say in the selection of early-access partners. Given that Palantir derives a large portion of its revenue from federal contracts, the order is seen as a disproportionate risk compared with rivals.

Record Revenue, Eye-Watering Valuation

The operational picture remains robust. In the first quarter of 2026, Palantir posted revenue of $1.63?billion, an 85% jump year-on-year. US revenue surged 104% to $1.282?billion, with the commercial segment climbing 133% to $595?million. Earnings per share of $0.33 beat the consensus estimate of $0.28. Net margin stood at 43.67% and return on equity at 28.34%. Management raised its full-year guidance to $7.65?7.66?billion, implying roughly 71% growth.

Strategic tailwinds include the Pentagon’s formal recognition of the Maven AI system as a permanent defence department programme, plus contract renewals with the US Army and Department of Agriculture. But stock-based compensation totalled $202?million in the first quarter alone, weighing on GAAP profitability and fuelling valuation scepticism.

Analysts rate the shares as a consensus “Moderate Buy.” Price targets range wildly from $90 (RBC) to $255 (BofA), with a mean near $185. Yet the trailing price-to-earnings multiple of 171 bakes in extreme growth expectations, and competition from Microsoft Azure, AWS, Google Cloud, OpenAI, and Anthropic is intensifying.

The AGM will provide a platform for institutional voices to be heard, even if the voting outcome is predetermined. With the NHS contract under political scrutiny, insider selling at a record pace, and a White House order targeting AI vendors, Palantir’s next quarterly report on 3 August will be a key test of whether the fundamental story can outweigh the gathering clouds.